Evaluates cost-effectiveness of fixed combinations for allergic rhinitis, suggesting potential for improved therapy options.
Allergic rhinitis (AR) remains a significant medical and social problem that requires effective and cost-effective approaches to therapy. The article discusses the pharmacoeconomic rationale for using fixed combinations (FC): mometasone furoate+azelastine, mometasone furoate+olopatadine, in comparison with the combination of fluticasone propionate+azelastine. The article analyzes the clinical efficacy, safety profile, and impact on patients’ quality of life in the context of direct
No takes yet. Share an insight, caveat, or question.
N.S. Tataurshchikova (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: